Biomea Fusion, Inc. (BMEA)
Largest Insider Buys in Sector
BMEA Stock Price History Chart
BMEA Stock Performance
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Activity of Biomea Fusion, Inc.
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $155,961 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $8.28M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (director) — $100,600. Valle Franco (Chief Financial Officer) — $55,361.
The last purchase of 10,000 shares for transaction amount of $100,600 was made by Hitchcock Michael J.M. (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Biomea Fusion, Inc.
| 2024-09-30 | director | 10,000 0.029% | $10.06 | $100,600 | -20.59% | |||
| 2024-06-11 | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +57.45% | |||
| 2023-06-01 | Sale | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.40% | ||
| 2023-05-31 | Sale | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.18% | ||
| 2023-05-12 | Sale | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.60% | ||
| 2023-05-09 | Sale | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.17% | ||
| 2023-05-08 | Sale | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.59% | ||
| 2023-04-20 | Sale | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.70% | ||
| 2023-03-31 | Sale | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.44% | ||
| 2023-03-30 | 400,000 1.2695% | $30.00 | $12M | -47.04% | ||||
| 2022-11-14 | director | 5,000 0.0169% | $7.93 | $39,650 | +88.46% | |||
| 2022-11-11 | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.01% | |||
| 2022-08-16 | 30,684 0.1067% | $13.87 | $425,648 | -9.74% | ||||
| 2022-07-21 | Sale | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | |||
| 2022-06-24 | Sale | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | |||
| 2022-01-14 | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% | |||
| 2021-09-17 | director | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | |||
| 2021-09-17 | 10 percent owner | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | |||
| 2021-08-23 | President & COO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% | |||
| 2021-08-23 | CEO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% |
Insider Historical Profitability
| Valle Franco | Chief Financial Officer | 42500 0.1173% | $4.01 | 3 | 0 | +36.31% |
| Hitchcock Michael J.M. | director | 15000 0.0414% | $4.01 | 2 | 0 | +88.46% |
| Stergiopoulos Sotirios | director | 4400000 12.1417% | $4.01 | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 9.8538% | $4.01 | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 9.6582% | $4.01 | 2 | 9 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $80.07M | 14.9 | 5.36M | 0% | +$0 | 0.01 | |
| State Street | $67.06M | 12.48 | 4.49M | +232.03% | +$46.86M | <0.01 | |
| Cormorant Asset Management Lp | $53.38M | 9.93 | 3.57M | 0% | +$0 | 2.49 | |
| Laurion Capital Management LP | $40.68M | 7.57 | 2.72M | -0.56% | -$229,990.80 | 0.29 | |
| Baker Bros Advisors LP | $31.53M | 5.87 | 2.11M | 0% | +$0 | 0.23 |